URAL Sodium Bicarbonate / Sodium Citrate / Citric Acid / Tartaric Acid 1760mg / 630mg / 720mg / 890mg per sachet Effervescent Granule 4g x 1's
RXDRUG-DR-XY36847-1pc
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Urinary alkalinization where indicated in the treatment of urinary tract infection (UTI); symptomatic relief of dysuria; enhance the action of certain antibiotics especially some sulphonamides, streptomycin, kanamycin, gentamicin; in gout especially when treated with uricosurics and possibly allopurinol; symptomatic treatment of gastric hyperacidity.
Dosage/Direction for Use
4-8 g (1-2 sachets) dissolved in cold water 4 times daily. Adults: 4-8 g in half a glass of cold water, 3-4 times daily, taken on an empty stomach after effervescence has subsided. Additional water (approximately ½ glass) should subsequently be ingested.
Children 6-12 years: 4 g in half a glass of cold water, 2-3 times daily, taken on an empty stomach after effervescence has subsided. Additional water (approximately ½ glass) should subsequently be ingested.
Children 6-12 years: 4 g in half a glass of cold water, 2-3 times daily, taken on an empty stomach after effervescence has subsided. Additional water (approximately ½ glass) should subsequently be ingested.
Contraindications
Renal failure or hypernatremia; in conjunction with hexamine mandelate or hexamine hippurate therapy because an acidic urine is needed.
Caution is advised in overt and occult cardiac failure. Concomitant use of urinary alkalinizers and quinolone antibiotics should be avoided. Crystalluria may be more likely to occur in alkaline urine.
Caution is advised in overt and occult cardiac failure. Concomitant use of urinary alkalinizers and quinolone antibiotics should be avoided. Crystalluria may be more likely to occur in alkaline urine.
Special Precautions
Ural contains sodium 644 mg/sachet which should be taken into account by those on a low sodium diet.
Ural should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema and preeclampsia.
The clinical condition of the patient should be evaluated and laboratory determinations (eg, serum electrolytes, acid-base balance) obtained periodically during Ural therapy, particularly in patients with renal disease.
Use in pregnancy: Studies regarding the effect of citrates on pregnancy have not been done.
Use in lactation: Caution should be exercised when administered to a nursing mother.
Ural should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema and preeclampsia.
The clinical condition of the patient should be evaluated and laboratory determinations (eg, serum electrolytes, acid-base balance) obtained periodically during Ural therapy, particularly in patients with renal disease.
Use in pregnancy: Studies regarding the effect of citrates on pregnancy have not been done.
Use in lactation: Caution should be exercised when administered to a nursing mother.
Use In Pregnancy & Lactation
Use in pregnancy: Studies regarding the effect of citrates on pregnancy have not been done.
Use in lactation: Caution should be exercised when administered to a nursing mother.
Use in lactation: Caution should be exercised when administered to a nursing mother.
Adverse Reactions
The tartrate component of Ural may be incompletely absorbed. Because of this, Ural may exert a mild laxative effect. Prolonged and excessive use may cause systemic alkalosis and/or hypernatremia.
Drug Interactions
General: Alkalinization of the urine due to the use of Ural, theoretically, may result in a decreased therapeutic effect of the following medications: Chlorpropamide, lithium, salicylates and tetracyclines. Alternatively, alkalinization of the urine due to the use of Ural, theoretically, may result in an increased therapeutic effect of the following medications: Amphetamines, ephedrine/pseudoephedrine.
Antacids: Concurrent use of antacids with citrates may result in systemic alkalosis. Concomitant administration of antacids with sodium citrate and sodium bicarbonate may promote the development of calcium stones in patients with uric acid stones and may also cause hypernatremia. Concurrent use of aluminum-containing antacids with citrate salts can increase aluminum absorption, possibly resulting in acute aluminum toxicity, especially in patients with renal insufficiency.
Quinolones: Citrates may reduce the solubility of ciprofloxacin, norfloxacin or ofloxacin in the urine. Patients should be observed for signs of crystalluria and nephrotoxicity.
Laxatives: Concurrent administration of citrates with laxatives may have an additive effect.
Antacids: Concurrent use of antacids with citrates may result in systemic alkalosis. Concomitant administration of antacids with sodium citrate and sodium bicarbonate may promote the development of calcium stones in patients with uric acid stones and may also cause hypernatremia. Concurrent use of aluminum-containing antacids with citrate salts can increase aluminum absorption, possibly resulting in acute aluminum toxicity, especially in patients with renal insufficiency.
Quinolones: Citrates may reduce the solubility of ciprofloxacin, norfloxacin or ofloxacin in the urine. Patients should be observed for signs of crystalluria and nephrotoxicity.
Laxatives: Concurrent administration of citrates with laxatives may have an additive effect.
Storage
Store at temperatures not exceeding 30°C.
Action
Urinary and gastric alkalinizer.
MedsGo Class
Other Drugs Acting on the Genito-Urinary System
Features
Brand
Ural
Full Details
Dosage Strength
1760mg / 630mg / 720mg / 890mg / sachet
Drug Ingredients
- Bicarbonate
- Citrate
- Citric Acid
- Tartaric Acid
Drug Packaging
Effervescent Granule 4g x 1's
Generic Name
Sodium BiCarbonate / Sodium Citrate / Citric Acid / Tartaric Acid
Dosage Form
Effervescent Granule
Registration Number
DR-XY36847
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply